Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …

Computationally guided semirational design has significant potential for improving the
aggregation kinetics of protein biopharmaceuticals. While improvement in the global …

With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …

Antibodies are highly soluble, multidomain proteins that are well suited for
biopharmaceutical development; however, engineering antibodies to perform novel …

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …

Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

Aggregation of monoclonal antibodies is often a multi‐step process involving structural
alterations in monomeric proteins and subsequent formation of soluble or insoluble …

Antibody fragments are used in the clinic as important therapeutic proteins for treatment of
indications where better tissue penetration and less immunogenic molecules are needed …